In conclusion, our study provides real-world clinical evidence that high baseline PD-L1 expression is an adverse prognostic factor in patients with advanced EGFR-mutated lung adenocarcinoma receiving first-line osimertinib therapy. This evidence concerns the gene EGFR and lung adenocarcinoma.